Cargando…

Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period

Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Fumio, Watanabe, Keisuke, Shinkai, Masaharu, Tei, Yoshitaka, Mishina, Kei, Tanabe, Mikiko, Ishii, Hiroshi, Shinoda, Masahiro, Shimokawaji, Tadasuke, Kudo, Makoto, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930592/
https://www.ncbi.nlm.nih.gov/pubmed/27370896
http://dx.doi.org/10.1186/s40880-016-0127-x
_version_ 1782440766840242176
author Asano, Fumio
Watanabe, Keisuke
Shinkai, Masaharu
Tei, Yoshitaka
Mishina, Kei
Tanabe, Mikiko
Ishii, Hiroshi
Shinoda, Masahiro
Shimokawaji, Tadasuke
Kudo, Makoto
Kaneko, Takeshi
author_facet Asano, Fumio
Watanabe, Keisuke
Shinkai, Masaharu
Tei, Yoshitaka
Mishina, Kei
Tanabe, Mikiko
Ishii, Hiroshi
Shinoda, Masahiro
Shimokawaji, Tadasuke
Kudo, Makoto
Kaneko, Takeshi
author_sort Asano, Fumio
collection PubMed
description Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period.
format Online
Article
Text
id pubmed-4930592
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49305922016-07-06 Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period Asano, Fumio Watanabe, Keisuke Shinkai, Masaharu Tei, Yoshitaka Mishina, Kei Tanabe, Mikiko Ishii, Hiroshi Shinoda, Masahiro Shimokawaji, Tadasuke Kudo, Makoto Kaneko, Takeshi Chin J Cancer Case Report Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period. BioMed Central 2016-07-02 /pmc/articles/PMC4930592/ /pubmed/27370896 http://dx.doi.org/10.1186/s40880-016-0127-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Asano, Fumio
Watanabe, Keisuke
Shinkai, Masaharu
Tei, Yoshitaka
Mishina, Kei
Tanabe, Mikiko
Ishii, Hiroshi
Shinoda, Masahiro
Shimokawaji, Tadasuke
Kudo, Makoto
Kaneko, Takeshi
Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title_full Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title_fullStr Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title_full_unstemmed Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title_short Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
title_sort relapse of both small cell lung cancer and lambert–eaton myasthenic syndrome after a 13-year disease-free survival period
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930592/
https://www.ncbi.nlm.nih.gov/pubmed/27370896
http://dx.doi.org/10.1186/s40880-016-0127-x
work_keys_str_mv AT asanofumio relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT watanabekeisuke relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT shinkaimasaharu relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT teiyoshitaka relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT mishinakei relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT tanabemikiko relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT ishiihiroshi relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT shinodamasahiro relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT shimokawajitadasuke relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT kudomakoto relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod
AT kanekotakeshi relapseofbothsmallcelllungcancerandlamberteatonmyasthenicsyndromeaftera13yeardiseasefreesurvivalperiod